Skip Navigation



Carcinogenesis Advance Access published online on September 28, 2006
Carcinogenesis, doi:10.1093/carcin/bgl168
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
28/3/632    most recent
bgl168v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Jun, Y.
Right arrow Articles by Wang, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jun, Y.
Right arrow Articles by Wang, X.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Received December 29, 2005
Revised August 2, 2006
Accepted August 13, 2006

CANCER PREVENTION

Gambogic acid induced G2/M phase cell cycle arrest via disturbing CDK7 mediated phosphorylation of CDC2/P34 in human gastric carcinoma BGC-823 cells

Yu Jun 1 {dagger}, Qing-Long Guo 1 {dagger}, Qi-Dong You 2 *, Li Zhao 1, Hong-Yan Gu 1, Yong Yang 1, Hai-wei Zhang 1, Zi Tan 3, and Xiaotang Wang 3

1 Department of Physiology, China Pharmaceutical University, Nanjing 210009, People's Republic of China
2 Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, People's Republic of China
3 Department of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA

* To whom correspondence should be addressed.
Qi-Dong You, E-mail: anticancer_drug{at}yahoo.com.cn


  Abstract

Molecular mechanisms of cell cycle arrest caused by gambogic acid (GA), a natural product isolated from the gamboge resin of Garcinia hanburryi tree, has been investigated using BGC-823 human gastric carcinoma cells as a model. Based on our 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay and flow cytometric analysis, treatment of BGC-823 cells with growth suppressive concentrations of GA caused an irreversible arrest in the G2/M phase of the cell cycle. Western blot analysis demonstrated that GA induced cell cycle arrest in BGC-823 cells was associated with a significant decrease in CDC2/P34 synthesis, which led to the accumulation of phosphorylated-Tyr 15 (inactive) form of CDC2/P34. Real-time PCR, Western blot, and kinase activity assays revealed that GA induced reduction of CDC2/P34 expression was mediated through the inhibition of cyclin-dependent kinase (CDK)-activating kinase (CDK7/cyclin H) activity. In addition, GA treated cells were shown to have a low level of CDK7 kinase-phosphorylated-Thr 161 CDC2/P34 (active). Taken together, our results suggested that the inhibited proliferation of GA treated BGC-823 cells was associated with the decreased production of CDK7 mRNA and protein, which in turn, resulted in the reduction of CDK7 kinase activity in GA treated cells. The reduced CDK7 kinase activity is responsible for the inactivation of CDC2/P34 kinase and the irreversible G2/M phase cell cycle arrest of human gastric carcinoma BGC-823 cells.

{dagger}These authors contributed equally to this work.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
B. B. Aggarwal, M. E. Van Kuiken, L. H. Iyer, K. B. Harikumar, and B. Sung
Molecular Targets of Nutraceuticals Derived from Dietary Spices: Potential Role in Suppression of Inflammation and Tumorigenesis
Experimental Biology and Medicine, August 1, 2009; 234(8): 825 - 849.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Gu, X. Wang, S. Rao, J. Wang, J. Zhao, F. L. Ren, R. Mu, Y. Yang, Q. Qi, W. Liu, et al.
Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells
Mol. Cancer Ther., October 1, 2008; 7(10): 3298 - 3305.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Zhai, C. Jin, C.-w. Shiau, S. Kitada, A. C. Satterthwait, and J. C. Reed
Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins
Mol. Cancer Ther., June 1, 2008; 7(6): 1639 - 1646.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Yi, Z. Yi, S.-G. Cho, J. Luo, M. K. Pandey, B. B. Aggarwal, and M. Liu
Gambogic Acid Inhibits Angiogenesis and Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2 Signaling
Cancer Res., March 15, 2008; 68(6): 1843 - 1850.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Abbas, A. Bhoumik, R. Dahl, S. Vasile, S. Krajewski, N. D.P. Cosford, and Z. A. Ronai
Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma
Clin. Cancer Res., November 15, 2007; 13(22): 6769 - 6778.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. K. Pandey, B. Sung, K. S. Ahn, A. B. Kunnumakkara, M. M. Chaturvedi, and B. B. Aggarwal
Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-{kappa}B signaling pathway
Blood, November 15, 2007; 110(10): 3517 - 3525.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S.-W. Jang, M. Okada, I. Sayeed, G. Xiao, D. Stein, P. Jin, and K. Ye
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death
PNAS, October 9, 2007; 104(41): 16329 - 16334.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.